Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Conditions
Keywords
neoplasms, registry, health services research, epidemiology, Germany, palliative treatment, palliative care
Brief summary
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
Detailed description
SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to two years.
Interventions
OTHERRoutine care as per site standard
Physician's choice according to patient's needs. Routine care as per site standard.
Sponsors
iOMEDICO AG
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC * Planned palliative systemic first-line therapy * Age \>= 18 years * Signed informed consent (IC) * Patients answering questionnaires: IC before first therapy cycle * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle
Exclusion criteria
* No systemic therapy for ESCC, EAC, GAC or GEJAC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Course of treatment (treatment reality) | 2 years per patient | Documentation of anamnestic data and therapy sequences |
Countries
Germany
Contacts
CONTACTAdrian Binninger
STUDY_CHAIRTobias Dechow, Prof.
Ravensburg
STUDY_CHAIRFlorian Lordick, Prof.
Leipzig
STUDY_CHAIRSylvie Lorenzen, Prof.
München
STUDY_CHAIRKarin Potthoff, Dr.
Freiburg
STUDY_CHAIRAnke Reinacher-Schick, Prof.
Bochum
Outcome results
None listed